Attyloid

Executive Summary

Attyloid is a German diagnostics company developing the sFIDA platform, a cutting-edge technology for quantitative detection of single oligomers and aggregates—key biomarkers for CNS disorders such as Alzheimer’s and Parkinson’s diseases. Currently in Phase 1 development, the platform aims to enable early and accurate diagnosis of neurodegenerative conditions, addressing a critical unmet need. By targeting the pathological aggregates themselves, sFIDA offers potential advantages over existing methods in sensitivity and specificity. Attyloid’s progress through early clinical stages positions it to attract partnerships and funding, though financial and operational details remain limited. With a focus on high-impact CNS diseases, the company’s technology could significantly advance biomarker-based diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 1 clinical study70% success
• Q4 2026Strategic partnership with pharmaceutical company50% success
• Q2 2026Publication of validation data in peer-reviewed journal80% success